As Seen In

As Seen In

Vancouver hair-loss biotech wins Japanese patent


Vancouver-based RepliCel Life Sciences Inc., a clinical stage biopharmaceutical company, has been granted a patent by Japan’s Ministry of International Trade and Industry for the applied use of hair follicle mesenchymal stem cells, the company announced January 13.

These cells are used in RepliCel’s treatment for androgenetic alopecia, also known as pattern hair loss.

RepliCel now has patents issued in Japan, the United States, Australia and the European Union, with other jurisdictions still pending.

RepliCel said the patent approval is an important milestone as its licensing partner, Shiseido Company, prepares to conduct human clinical trials using RCH-01. Shiseido has an exclusive license to use RCH-01 in Japan, China, South Korea, Taiwan and the ASEAN countries representing a population of approximately 2.1 billion people.

According to the International Society of Hair Restoration, almost one million patients sought treatment for hair loss in 2012. Of this number, 41% of the patients were from Asia, representing the largest single region, surpassing the United States by 15%.

The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.